MFN Pricing Model Threatens New Drug Launches and Clinical Trials in Sweden, Warns Lif

The implementation of the Most Favored Nation (MFN) pricing model, which ties U.S. pharmaceutical prices to the lowest prices among a select group of countries, is raising significant concerns for Sweden's pharmaceutical market. Lif, the Swedish organization representing research-based pharmaceutical companies, warns that this model could lead to fewer new drug launches and a decline in clinical trials within the country.

According to a recent survey by Lif, 57% of pharmaceutical companies are considering refraining from launching certain new drugs in Sweden over the next three years. Additionally, 86% anticipate delays in drug launches during the same period, reflecting a widespread caution among industry players. The survey also revealed that one in three companies fears withdrawing existing drugs from the Swedish market, while two-thirds predict a decrease in the number of clinical trials conducted in Sweden.

Lif's CEO, Sofia Wallström, emphasized the gravity of these findings, stating, "There have been clear and serious signals for some time indicating that companies are forced to delay new drug launches because of the MFN model." She explained that since the U.S. pricing is anchored to the lowest prices elsewhere, including Sweden where prices tend to be lower, pharmaceutical companies must carefully evaluate the broader consequences across multiple markets. This interconnected pricing strategy could compel companies to limit their activities in Sweden.

Wallström further warned, "If companies exclude Sweden from launches and clinical studies, it would directly affect our country’s ability to maintain and attract world-leading research." The potential reduction in access to new pharmaceuticals and diminished research opportunities poses a significant challenge to Sweden's healthcare system and its global standing in biomedical innovation.

With these developments, Lif underscores the urgent need for policymakers to consider the ramifications of the MFN model on Sweden’s pharmaceutical landscape and research environment to safeguard future access to cutting-edge treatments and clinical studies.